Literature DB >> 29063251

Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC.

Chae Jung Park1, Chansik An1, Sumi Park2, Jin-Young Choi1, Myeong-Jin Kim3.   

Abstract

OBJECTIVES: To investigate the significance of subcentimetre (≤1 cm) arterially enhancing and hepatobiliary hypointense lesions (SAELs) observed on gadoxetic acid-enhanced magnetic resonance imaging (MRI) of patients at risk of hepatocellular carcinoma (HCC).
METHODS: A SAEL was defined as a subcentimetre hypervascular nodule exhibiting a hepatobiliary phase defect on gadoxetic acid-enhanced MRI. We included 52 SAELs from 46 patients in a HCC surveillance population. The HCC reference standard was pathologic confirmation or a nodule >1 cm with typical imaging features of HCC at follow-up imaging. The malignancy rate and HCC-favourable imaging findings of SAELs were evaluated.
RESULTS: The malignancy rate among SAELs was 57.7% (30/52). At diagnosis, all SAELs that progressed to overt HCC were treatable with curative intention. Venous or late dynamic phase washout was more frequently observed with malignant SAELs than with benign SAELs (57.7% vs. 30.6%; P = 0.01). If SAELs exhibiting washout were considered as HCC, sensitivity, specificity, and positive predictive value was 83.3%, 50%, and 69.4%, respectively.
CONCLUSION: Among patients at risk of HCC, SAELs on gadoxetic acid-enhanced MRI exhibited high malignant potential. However, close observation may be an appropriate strategy for isolated SAELs. A washout appearance may be helpful for predicting malignancy. KEY POINTS: • Gadoxetic acid-enhanced MRI provides hepatobiliary phase (HBP) images. • Screening frequently detects subcentimetre arterially enhancing and hepatobiliary hypointense lesions (SAELs). • A majority of SAELs progressed to overt HCC within 2 years. • A venous-phase washout appearance correlated significantly with malignancy in SAELs.

Entities:  

Keywords:  Diagnosis; Gadoxetic acid; Hepatocellular carcinoma; Magnetic resonance imaging; Sensitivity and specificity

Mesh:

Substances:

Year:  2017        PMID: 29063251     DOI: 10.1007/s00330-017-5088-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  16 in total

1.  Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis?

Authors:  Mustafa R Bashir; Rajan T Gupta; Matthew S Davenport; Brian C Allen; Tracy A Jaffe; Lisa M Ho; Daniel T Boll; Elmar M Merkle
Journal:  J Magn Reson Imaging       Date:  2012-09-25       Impact factor: 4.813

2.  Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging.

Authors:  Kyoung Doo Song; Seong Hyun Kim; Hyo Keun Lim; Sin-Ho Jung; Insuk Sohn; Hyung Sik Kim
Journal:  Eur Radiol       Date:  2015-03-04       Impact factor: 5.315

3.  Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging with gadoxetic acid detects additional lesions and increases overall survival.

Authors:  Hyung-Don Kim; Young-Suk Lim; Seungbong Han; Jihyun An; Gi-Ae Kim; So Yeon Kim; So Jung Lee; Hyung Jin Won; Jae Ho Byun
Journal:  Gastroenterology       Date:  2015-02-28       Impact factor: 22.682

Review 4.  Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.

Authors:  Yoon Jin Lee; Jeong Min Lee; Ji Sung Lee; Hwa Young Lee; Bo Hyun Park; Young Hoon Kim; Joon Koo Han; Byung Ihn Choi
Journal:  Radiology       Date:  2015-01-05       Impact factor: 11.105

5.  Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Joon Seok Lim; Hye-Suk Hong; Yong Eun Chung; Jin-Young Choi
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

6.  Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma.

Authors:  Tomoko Hyodo; Takamichi Murakami; Yasuharu Imai; Masahiro Okada; Masatoshi Hori; Yuki Kagawa; Sachiyo Kogita; Seishi Kumano; Masatoshi Kudo; Teruhito Mochizuki
Journal:  Radiology       Date:  2013-02       Impact factor: 11.105

Review 7.  Epidemiology of hepatocellular carcinoma: consider the population.

Authors:  Sahil Mittal; Hashem B El-Serag
Journal:  J Clin Gastroenterol       Date:  2013-07       Impact factor: 3.062

8.  Hypovascular hepatic nodules at gadoxetic acid-enhanced MRI: whole-lesion hepatobiliary phase histogram metrics for prediction of progression to arterial-enhancing hepatocellular carcinoma.

Authors:  Andrew B Rosenkrantz; Niveditha Pinnamaneni; Andrea S Kierans; Justin M Ream
Journal:  Abdom Radiol (NY)       Date:  2016-01

9.  Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.

Authors:  Kyung Mi Jang; Seong Hyun Kim; Young Kon Kim; Dongil Choi
Journal:  Acta Radiol       Date:  2014-05-16       Impact factor: 1.990

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  3 in total

Review 1.  Problematic lesions in cirrhotic liver mimicking hepatocellular carcinoma.

Authors:  Myeong-Jin Kim; Sunyoung Lee; Chansik An
Journal:  Eur Radiol       Date:  2019-02-20       Impact factor: 5.315

2.  The Course of LIRADS 3 and 4 Hepatic Abnormalities as Correlated With Explant Pathology: A Single Center Experience.

Authors:  Panita Mettikanont; Anita Kalluri; Therese Bittermann; Neil Phillips; Bao-Li Loza; Mark Rosen; Evan Siegelman; Emma Furth; Peter Abt; Kim Olthoff; Abraham Shaked; Maarouf Hoteit; K Rajender Reddy
Journal:  J Clin Exp Hepatol       Date:  2022-03-09

Review 3.  Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting.

Authors:  Cher Heng Tan; Shu-Cheng Chou; Nakarin Inmutto; Ke Ma; RuoFan Sheng; YingHong Shi; Zhongguo Zhou; Akira Yamada; Ryosuke Tateishi
Journal:  Korean J Radiol       Date:  2022-05-09       Impact factor: 7.109

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.